

WORLD **A**NTI-**M**ICROBIAL **R**ESISTANCE CONGRESS | 2019

FEATURING

PITCH & **P**ARTNER | 2019

November 7–8, 2019

Renaissance Hotel, Washington, DC

**THE ONLY COMMERCIALY FOCUSED
AMR CONFERENCE GLOBALLY**



OUR STORY

Since 2015, the World Anti-Microbial Resistance Congress has been the only commercially focused conference globally of its kind.

Launched during the release of key reports such as the AMR Review and A Scientific Roadmap for Antibiotic Discovery, the World AMR Congress has brought attention to the threats of this emerging crisis to the global healthcare system.

The conference gathers global leaders in infectious diseases to meet, brainstorm and discuss the challenges and opportunities on seven topic areas:

- Antibiotic R&D: advancing the development of antibiotic and non-traditional therapies and improving commercialization strategies
- Diagnostics: innovating the development and deployment of rapid diagnostics tests, while ensuring an effective integration into hospitals' workflow and reimbursement
- Antimicrobial stewardship: using technology to improve antibiotic prescription, monitoring and surveillance while advancing stewardship-based purchasing guidelines
- Pitch & Partner: joining funding and partnerships with antibiotics and diagnostics innovation
- Infection Control: advancing policies to improve infection prevention, control and compliance in healthcare facilities
- Manufacturing: overcoming challenges for a sustainable and controlled antibiotic manufacturing and supply chain
- Vaccines: discussing the clinical and economic value of vaccines to combat AMR

This November 7-8, 2019, 600 attendees from over 40 countries will be gathered at the Renaissance Washington, D.C. Downtown Hotel for the largest AMR conference ever.

We look forward to meeting you in D.C.



André Singer

General Manager – Life Sciences

T/ +1 646 619 1797

E/ andre.singer@terrapinn.com

Register now at www.terrapinn.com/antimicrobial







Jonathan Van-Tam

Deputy Chief Medical Officer
UK Department of Health


KEYNOTE ADDRESS: UK's efforts to combat resistance and create a sustainable commercial environment for existing and future antibiotics

FACTS & FIGURES

ANTIMICROBIAL RESISTANCE STATS – WHY WE NEED TO TAKE ACTION



KEYNOTE PANEL: ANALYZING THE POTENTIAL IMPACT OF CURRENT COMMERCIAL AND 'PULL' INITIATIVES



Amanda Jezek, Senior Vice President, Public Policy and Government Relations, **Infectious Diseases Society of America**



Kevin Outterson, Professor, **Boston University**, Executive Director, **CARB-X**



Aleks Engel, Director, REPAIR Impact Fund, **Novo Holdings**



Melissa Stundick, Executive Director, Strategic Alliances, **Spero Therapeutics**



Jeremy Knox, Director of Policy, Drug Resistant Infections, **Wellcome Trust**



Evan Loh, Chairman, **Antimicrobials Working Group**, President, Chief Operating Officer, Chief Medical Officer, **Paratek Pharmaceuticals**

* WHO's Report No Time to Wait: Securing the future from drug-resistant infections

** CDC's Report Antibiotic Resistance Threats in the United States, 2013

*** OCDE's Report Stemming the superbug tide: Just a few dollars more. November 7, 2018.

ANTIBIOTIC DEVELOPMENT



This track covers everything from discovery through to commercialization and payment reform. Learn about the latest innovative pre-clinical, clinical, commercial pathways, and best practices in traditional and non-traditional antibiotic development. Dive into conversations on “pull” incentives with industry leaders, heads of commercial development and policymakers.



MARK ALBRECHT
Chief (Acting), Antibacterials Program



SARANSH CHAUDHARY
Chief Executive Officer



SHEILA CONNELLY
Vice President of Research



MICHAEL P. BEVILACQUA
Chief Executive Officer



CARA CASSINO
Chief Medical Officer and Executive Vice President of Research and Development



JENNY HELLMAN
Analyst



MONIKA SCHNEIDER
Research Associate



PETER BEYER
Senior Advisor



MANOS PERROS
Chief Executive Officer



MIKE DUDLEY
President & Chief Executive Officer



DAVID ROBLIN
Chief Operating Officer, Chief Medical Officer, President of R&D



GUY MACDONALD
President and Chief Executive Officer



MARINA KOZAK
Biologist, Division of CBRN Countermeasures








PAMELA TENAERTS
Executive Director



COLM LEONARD
Clinical Advisor



CHRISTINE ÅRDAL
Senior Advisor, EU-JAMRAI



DIAGNOSTICS



Diagnostics play a key role in curbing resistance and improving appropriate use of antimicrobials. Hear from diagnostic developers and heads of microbiology on innovative rapid diagnostics and antimicrobial susceptibility tests. Also featured are the presentations from hospitals and pharmacists on the uptake and use of new diagnostics within the hospital setting.



RIBHI SHAWAR

Branch Chief, Division of Microbiology, CDRH OVD



CASSANDRA KELLY

Director, Emerging Threats



ERIC WENZLER

Assistant Professor, Department of Pharmacy Practice



KARTIK CHERABUDDI

Director, Antimicrobial Stewardship Program and Hospital Epidemiologist



MARY MOTYL

Director of Clinical Microbiology



ROBERT SAMBURSKY

President and Chief Executive Officer



HERMAN GOOSSENS

Project Leader, Value-DX, Director of Research, Laboratory of Medical Microbiology



TOM LOWERY

Chief Scientific Officer



EPHRAIM TSALIK

Professor



NEIL CLANCY

Associate Professor of Medicine, Infectious Diseases Division, and Director, Mycology Program



FATIMA BRAKTA

Pharmacy Clinical Manager



ED SEPTIMUS

Professor Internal Medicine



CECILE BALDING

Microbiology Supervisor



CHRISTOPHER DOERN

Director of Clinical Microbiology



IAN CRITCHLEY

Vice President, Microbiology



BAOMING LIU

Clinical Laboratory Specialist



INFECTION CONTROL



Preventing infection is one of the most effective and proactive strategies to help curb the spread of resistance. Hear from directors of infection control within hospital and global healthcare leaders on best practices for resistant pathogen protocols, practitioner education and infection prevention strategies.



JAY VARMA
Senior Advisor



CHRISTIAN LILLIS
Executive Director



CLIFFORD MCDONALD
Associate Director for Science, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Disease



ANGELLA BROWNE
Infection Control Officer



MICHELLE A. BARRON
Medical Director, UCH Infection Prevention and Control, Professor of Medicine



EILI KLEIN
Senior Fellow



KERRY LAPLANTE
President Society of Infectious Diseases Pharmacists, Professor of Pharmacy, University of Rhode Island, Adjunct Professor of Medicine, Brown University



JEFFREY SILVERS
Medical Director of Pharmacy and Infection Control



DANIEL MORGAN
Associate Professor, Epidemiology & Public Health



MARISA GLUCOFT
Director, Infection Prevention Control




LINDA LYBERT
Founder and Executive Director



KAREN HOFFMAN
President



MARY MILLARD
Patient advocate



MICHAEL CRAIG
Senior Advisor for Antibiotic Resistance, Antibiotic Resistance Coordination and Strategy Unit



AMY KIRBY
Senior Service Fellow



THOMAS HEYMANN
President & Executive Director



STEWARDSHIP



As approaches to antimicrobial stewardship evolve, so do specific stewardship programs, initiatives and practices. Hear from hospitals, industry, insurance companies and stewardship experts on the most innovative approaches to curb resistance and implement appropriate use of antimicrobials.



MIKE OSTERHOLM
Director, Center for Infectious Disease Research and Policy (CIDRAP)



DANIEL KNECHT
VP of Health Strategy & Innovation



JILL MASSEY
Senior Vice President, Medical Affairs



ERICA WASHINGTON
Healthcare-associated Infections and Antibiotic Resistance Program Coordinator



KIM ABBASS
Clinical Coordinator, Antimicrobial Stewardship, Eastern Zone



LIZA VAEZI
Co-Director Antimicrobial Stewardship Program/ Coordinator Pharmacy and Therapeutics, Virginia Mason Medical Center, Clinical Associate Professor



CHARLEY JOHN
Director, US Public Policy



THOMAS CUENI
Director-General, IFPMA, Chairman



DEBBIE GOFF
Infectious Diseases Specialist, The Ohio State University Wexner Medical Center, Clinical Associate Professor



JASON POGUE
President-Elect



RICK SIBBEL
Former Executive Director, US Food Animal Business Unit



KALVIN YU
Medical Director
BD Digital Health MedMined



ADAM ZERDA
Director, AMR Strategy and Development




JAYASREE IYER
Executive Director



EDDIE STENEHJEM
Medical Director, Antibiotic Stewardship



MATTHEW GOETZ
Chief, Infectious Diseases



PITCH&PARTNER 2019

PRESENTATIONS



KAREN GALLANT

Research and Development Chief (Acting), Voting member of the Joint Oversight Committee



JEAN-PIERRE PACCAUD

Director, Business Development and Corporate Strategy



PETER JACKSON

Director



WALTER STOCKINGER

Managing Partner



MARY SCHAHEEN

President and Director



CRISTINA MONTERO

Associate Director



MARK ENGEL

Chief Executive Officer



PITCHES



ALEXANDER BELCREDI

Chief Executive Officer



MATHEW UPTON

Founder and Chief Scientific Officer



DAVID LUCI

Chief Executive Officer



GREG MERRIL

Chief Executive Officer



NEIL CLARK

Chief Executive Officer



MARC GITZINGER

Chief Executive Officer & Co-Founder



RUSTY BROMLEY

Chief Operating Officer



MARC LEMONNIER

Chief Executive Officer



MARIA NAGY

Chief Executive Officer



MATTHEW GOMBRICH

Chief Medical Officer



PIOTR GARSTECKI

Chief Executive Officer



MONIQUE VAN HOEK

Professor School of Systems Biology



As funding remains a major hurdle for antibiotic and rapid diagnostics development, hear the perspective of current funding agencies and initiatives such as CARB-X, GARDP, and AMR Centre, as well as successful partnering and capital case studies that contributed to advancing the development of innovative antimicrobials and rapid tests. Over 20+ cutting edge biotechs, academic innovators and diagnostics developers will be presenting new data to prospective funders and partners.

VACCINES & ANTIBIOTIC MANUFACTURING



VACCINES

Vaccines can play key role in combatting the spread of resistance, yet they have been a historically under recognized as a tool for fighting AMR. Hear from biotechs, pharmaceutical companies and funders on both the integration of vaccines into AMR strategies, as well as innovative vaccine development.



MERRIBETH MORIN
Alliance Director



JIM WASSIL
Business Unit Lead, Vaccines, Patient & Health Impact



ALLISON FLINN
Associate Director, Public Policy and Government Relations



JAVAD AMAN
President and Chief Scientific Officer



JACQUELINE MILLER
Vice President and Head, Clinical R&D, US Vaccine Research and Development Center



ANTIBIOTIC MANUFACTURING

Antibiotic manufacturing has several key components impacting the spread of resistance: product quality, waste management and sustainable supply chains. These key elements affect both the efficiency for the manufacturer and also the spread of antimicrobial waste in the environment. Hear from large pharma, generic manufacturers, biotechs, and CMOs/CDMOs on how to improve manufacturing processes to prevent antimicrobial resistance.



GABRIELLE BREUGELMANS
Director of Research



JAIDEEP GOGTAY
Senior Vice President, Global Chief Medical Officer



ALBA TILEY
Head of Sustainability



JACQUES DUMAS
Chief Scientific Officer



STEVE BROOKS
Advisor



DALE L. STEMPLE
Head Global EHS - North America and EMEA, Global Environmental, Health and Safety



200+ SPEAKERS INCLUDING



JENNY HELLMEN
Analyst
Public Health Agency of Sweden



COLM LEONARD
Clinical Advisor
NICE



JAY VARMA
Senior Advisor
Africa CDC



DANIEL KNECHT
VP of Health Strategy & Innovation
CVS Health



CHRISTINE ARDAL
Senior Advisor, EU-JAMRAI
Norwegian Institute of Public Health



PETER BEYER
Senior Advisor, World Health
Organization




CHRISTIAN LILLIS
Executive Director
Peggy Lillis Foundation



CHARLEY JOHN
Director, US Public Policy
Walgreen Co.



GABRIELLE BREUGELMANS
Director of Research
Access to Medicine Foundation



GIANCARLO FRANCESE
Board Member, AMR Industry Alliance,
Access Head, Social Impact and
Responsibility
Teva



GUY MACDONALD
President and Chief Executive Officer
Tetraphase Pharmaceuticals



DEBRA GOFF
Infectious Diseases Specialist, The Ohio
State University Wexner Medical
Center, Clinical Associate Professor, Ohio
State University Medical Center



JANE KNISELY
Program Officer, Bacteriology and
Mycology Branch
NIAID, NIH



KARTIK CHERABUDDI
Director, Antimicrobial Stewardship
Program and Hospital Epidemiologist
University of Florida



KERRY LAPLANTE
Professor of Pharmacy, University of
Rhode, Island, Adjunct Professor of
Medicine, Brown University



ALBA TILEY
Head of Sustainability
Centrient Pharmaceuticals



KEVIN OUTTERSON
Professor, Boston University, Executive
Director
CARB-X



MARY MILLARD
Patient Advocate
Sepsis Survivor



LINDA LYBERT
Founder and Executive Director
Healthcare Surfaces Institute



RICK SIBBEL
Former Executive Director, US Food
Animal Business Unit
Merck Animal Health



PETER JACKSON
Director
AMR Centre



STEVE BROOKS
Advisor
AMR Industry Alliance



JEANETTE MUCHA
CEO, Chief Science Officer and Co-
Founder
Scibac



JAVAD AMAN
President and Chief Scientific Officer
Integrated Biotherapeutics



BRIAN TSE
Project Officer
U.S. Department of Health and Human
Services (HHS)



EUGEN JIWAMALL
Senior Research Analyst, Technology
Evaluation & Medical Policy
Independence Blue Cross



JEREMY KNOX
Policy and Advocacy Lead, Drug-Resistant
Infections Program, Wellcome Trust



MICHELLE BARRON
Medical Director, UCH Infection Prevention
and Control
University of Colorado Denver



ABIGAIL COLSON
Lecturer, Department of Management
Science
University of Strathclyde Glasgow



FATIMA BRAKTA
Pharmacy Clinical Manager
University Medical Center of New
Orleans



MANOS PERROS
Chief Executive Officer, Entasis
Therapeutics



MIKE DUDLEY
President & Chief Executive Officer
Qpex Biopharma



NEIL CLANCY
Associate Professor of Medicine,
Infectious Diseases Division, and Director,
Mycology Program
University of Pittsburgh



NICK VAN HISE
Infectious Disease Clinical Pharmacy
Specialist, Research Coordinator
Metro Infectious Disease Consultants



ANGELLA BROWNE
Infection Control Officer
Howard University Hospital



JUSTINE ABELLA ROSS
Infectious Diseases Pharmacist, Chair
Antimicrobial Stewardship Program,
Department of Pharmacy Services
City of Hope National Medical Center



MONIQUE VAN HOEK
Associate Professor
George Mason University, College of
Science



MARCO TAGLIETTI
President, Chief Executive Officer
SCYNEXIS



ALEXANDER BELCREDI
Chief Executive Officer
PhagoMed Biopharma



GREG MERRIL
Chief Executive Officer
Adaptive Phage Therapeutics



MALCOLM THOMAS
Chief Executive Officer
Agile Sciences



DAVID LUCI
Chief Executive Officer
Acurx Pharmaceuticals



RICHARD VICKERS
Senior Vice President, and Chief Scientific
Officer, Anti-Infectives
Summit Therapeutics



KIM ABBASS
Clinical Coordinator, Antimicrobial
Stewardship, Eastern Zone
Nova Scotia Health Authority



ELI KLEIN
Senior Fellow
Center for Disease Dynamics,
Economics & Policy



JIM WASSIL
Business Unit Lead, Vaccines
Patient & Health Impact, Pfizer



JAIDEEP GOGTAY
Senior Vice President, Global Chief
Medical Officer
Cipla



SARANSH CHAUDHARY
Chief Executive Officer
Venus Medicine Research Centre



MARK ENGEL
Chief Executive Officer
Phagelux



THIERRY BERNARDI
Chief Executive Officer
Biofilm Pharma



ROBERT SAMBURSKY
President and Chief Executive Officer
RPS Diagnostics



NEIL CLARK
Chief Executive Officer
Destiny Pharma



WALTER STOCKINGER
Managing Partner
Hadean Ventures



JEFFREY SILVERS
Medical Director of Quality, Infection
Control and Pharmacy
Sutter Health



MONIKA SCHNEIDER
Research Associate
Duke-Margolis Center for Health Policy



MARIA NAGY
Chief Executive Officer
Quorum X Diagnostics



JASON POGUE
President-Elect
Society of Infectious Disease
Pharmacists (SIDP)



KAREN GALLANT
Research and Development Chief (Acting)
and voting member of the Joint Oversight
Committee
CARB-X



RUSTY BROMLEY
Chief Operating Officer
AyuVis Research



RYAN DAVIES
Chief Executive Officer
Curza

200+ SPEAKERS INCLUDING



EDDIE STENEHJEM
Medical Director, Antibiotic Stewardship
Intermountain Healthcare



MARY SCHAHEEN
President and Director
Prevail Partners



THOMAS HEYMANN
President & Executive Director
Sepsis Alliance



BRIAN LUBBERS
Director of the Clinical Microbiology
Kansas State Veterinary Diagnostic
Laboratory



SILAS HOLLAND
Director of Infectious Diseases Policy
Merck



MATTHEW GOMBRICH
Chief Medical Officer
Aperture Bio



ERIC WENZLER
Assistant Professor, Department of
Pharmacy Practice
University of Illinois at Chicago College
of Pharmacy



JILL MASSEY
Senior Vice President, Medical Affairs
Melinta Therapeutics



THOMAS FILE
Antimicrobial Stewardship Program at
Summa Health, Akron, President-Elect
Infectious Disease Society of America
(IDSA)



SUSAN DAVIS
Clinical Professor, Pharmacy Practice,
Wayne State University, Infectious
Diseases Pharmacist
Henry Ford Health System



ADAM ZERDA
Director, AMR Strategy and Development
BD



TERRY ROEMER
President and Chief Scientific Officer
Prokaryotics Inc.



MICHAEL CRAIG
Senior Advisor for Antibiotic Resistance,
Antibiotic Resistance Coordination and
Strategy Unit
Centers for Disease Control



ERICA WASHINGTON
Healthcare-associated Infections and
Antibiotic Resistance Program Coordinator
Louisiana Department of Health



MARC LEMONNIER
Chief Executive Officer
Antabio



ANTHONY LAKAVAGE
Senior Vice-President, Global External
Affairs
US Pharmacopia



ZAK ZIMMERMAN
CEO & Cofounder
Forge Therapeutics



ANAND ANANDKUMAR
Chief Executive Officer
Bugworks Research India



JOHN JOHNSON
Chief Executive Officer and Director
Melinta Therapeutics



MIKE OSTERHOLM
Director, Center for Infectious Disease
Research and Policy (CIDRAP)
University of Minnesota



CLIFF MCDONALD
Associate Director for Science, Division of
Healthcare Quality Promotion
National Center for Emerging and
Zoonotic Infectious Disease, Centers
for Disease Control



MICHAEL BEVILACQUA
Chief Executive Officer
Amicrobe



CARA CASSINO
EVP Research and Development and
Chief Medical Officer
Contrafect



DANIEL MORGAN
Associate Professor of Epidemiology and
Medicine
University of Maryland School of
Medicine



ED SEPTIMUS
Senior Lecturer, Department of Population
Medicine
Texas A&M Health Science Center



BRUCE ALTEVOGT
Vice President and Head External Medical
Engagement, Hospital Business Unit
Pfizer




SHEILA CONNELLY
Vice President, Research
Synthetic Biologics



PIOTR GARSTECKI
Chief Executive Officer
Bacteromic



DALE STEMPL
Vice-President Global EHS
Mylan



TOM TURCO
Clinical Pharmacist
Mercy Philadelphia Hospital



KALVIN YU
Medical Director
BD Digital Health MedMined



EVAN LOH
Chairman, Antimicrobials Working Group,
President, Chief Operating Officer, Chief
Medical Officer
Paratek Pharmaceuticals, Inc.



PAMELA TENAERTS
Executive Director
Clinical Trials Transformation
Initiative (CTTI)



MERRIBETH MORIN
Alliance Director
CARB-X



HERMAN GOOSSENS
Project Leader, VALUE-Dx, Director
of Research, Laboratory of Medical
Microbiology
University of Antwerp



MELISSA STUNDICK
Executive Director of Strategic Alliances
Spero Therapeutics




EPHRAIM TSALIK
Professor
Duke University School of Medicine



GARETH MORGAN
Global Portfolio Management
Shionogi



DENNIS MICHAEL DIXON
Chief Bacteriology and Mycology Branch
NIAID-NIH



JOHN PRENDERGAST
Chairman
Recce Pharmaceuticals



THOMAS CUENI
Director-General, IFPMA, Chairman
AMR Industry Alliance



LIZA VAEZI
Co-Director Antimicrobial Stewardship
Program/ Coordinator Pharmacy and
Therapeutics, Virginia Mason Medical
Center, Clinical Associate Professor
University of Washington



ALEKS ENGEL
Director, REPAIR Impact Fund
Novo Holdings



JAYASREE IYER
Executive Director
Access to Medicine Foundation



ALLISON FLINN
Lead, North America Public Policy
Merck
Animal Health




MARK ALBRECHT
Chief (acting) Antibacterials Branch
BARDA



JACQUES DUMAS
Chief Scientific Officer
Tetraphase Pharmaceuticals



AMANDA JEZEK
Senior Vice President, Public Policy and
Government Relations
Infectious Diseases Society of America



CASSANDRA KELLY
Director, Emerging Threats
FIND



DAVE OUSTEROUT
Chief Scientific Officer & Co-Founder
Locus Biosciences



DAVE POWELL
SVP, Research
Summit Therapeutics



GUL MADISON
Head of Infectious Disease
Mercy Philadelphia Hospital



JONATHAN VAN-TAM
Deputy Chief Medical Officer, UK
Department of Health



PAUL PLUMMER
Executive Director
National Institute of Antimicrobial
Resistance Research and Education
(NIAMRRE)



CRISTINA MONTERO
Associate Director
TechAtlas, RA Capital Management




RIBHI SHAWAR
Branch Chief, Division of Microbiology,
CDRH, OIVD
Food and Drug Administration




MARC GITZINGER
CEO and Co-Founder
BioVersys AG



JEAN-PIERRE PACCARD
Director of Business Development and
Corporate Strategy
Global Antibiotic R&D Partnership
(GARDP)



MARISA GLUCOFT
Director, Infection Prevention Control
Children's Hospital Los Angeles








WES KIM
Antibiotic Resistance Project
The Pew Charitable Trust

PLENARY KEYNOTES

CONCRETE COMMERCIAL INITIATIVES

8:40	Keynote address: A vision for a healthy antibiotic R&D ecosystem Kevin Outterson , Professor, Boston University, Executive Director, CARB-X	8:40
9:00	Keynote address: UK's efforts to combat resistance and create a sustainable commercial environment for existing and future antibiotics Jonathan Van-Tam , Deputy Chief Medical Officer, UK Department of Health	9:00
9:20	Sponsored keynote address TITLE SPONSOR SLOT If you are interested in sponsoring this session in the Antibiotic R&D Track, contact André Singer now at +1 646 619 1797 or andre.singer@terrapinn.com	9:00
9:40	Open panel & audience Q&A: Analyzing the potential impact of current commercial and "pull" initiatives Moderator: Kevin Outterson , Professor, Boston University, Executive Director, CARB-X Aleks Engel , Director, REPAIR Impact Fund, Novo Holdings Melissa Stundick , Executive Director, Strategic Alliances, Spero Therapeutics Jeremy Knox , Director of Policy, Drug Resistant Infections, Wellcome Trust Evan Loh , Chairman, Antimicrobials Working Group , President, Chief Operating Officer, Chief Medical Officer, Paratek Pharmaceuticals Amanda Jezek , Senior Vice President, Public Policy and Government Relations, Infectious Diseases Society of America	9:40
10:20	SPEED NETWORKING FOLLOWED BY NETWORKING COFFEE BREAK	10:20

	 ANTIBIOTIC R&D	 DIAGNOSTICS	 ANTIMICROBIAL STEWARDSHIP	 INFECTION CONTROL	 MANUFACTURING	 PITCH&PARTNER₂₀₁₉
	Early Development	Development	Stewardship Partnerships	Guidelines and Regulation	Supply Chain	Funding & Innovation
11:15	How synthetic antibiotic development can change the antibiotic treatment model John Prendergast , Chairman, Recce Pharmaceuticals	Diagnostic devices for antimicrobial susceptibility and resistance - FDA update on recent initiatives and advancements Ribhi Shawar , Branch Chief, Division of Microbiology, CDRH, OIVD, FDA	Overview of US and international stewardship initiatives and partnerships Mike Osterholm , Director, Center for Infectious Disease Resesarch and Policy (CIDRAP), University of Minnesota	Preventing infections in African health facilities through laws and standards Jay Varma , Senior Advisor, Africa Centres for Disease Control and Prevention	Ensuring a sustained availability of high-quality antibiotics - considerations for manufacturing, quality testing, transport, poor quality drugs, and the role of customers Jaideep Gogtay , Senior Vice President, Global Chief Medical Officer, Cipla	CARB-X – accelerating innovation to fight drug-resistant bacteria Karen Gallant , Research and Development Chief (Acting), Voting member of the Joint Oversight Committee, CARB-X
11:35	How BARDA incentivizes antibacterial development from early development through marketing approval Mark Albrecht , Chief (acting) Antibacterials Branch, BARDA	Thinking creatively about diagnostic development – breaking from constraints of conventional development and delivery models Cassandra Kelly , Director, Emerging Threats, FIND	Big data to improve antibiotic prescribing: CVS Health-Aetna's multi-stakeholder approach Daniel Knecht , VP of Health Strategy & Innovation, CVS Health	Examining the role of Infection Preventionists in combating AMR Karen Hoffman , University of North Carolina School of Medicine Chapel Hill, President, APIC	Collaborating along the value chain for sustainably made antibiotics: roles of manufacturers and buyers Alba Tiley , Head of Sustainability, Centrient Pharmaceuticals	Utilizing bacteriophages to prevent infections: an update Mark Engel , Chief Executive Officer, Phagelux
11:55	Oral Ceftriaxone - a proof-of-concept for a novel drug delivery platform Saransh Chaudhary , Chief Executive Officer, Venus Medicine Research Centre	Host-based diagnostics for discriminating bacterial and viral infection – diagnostic performance in patients in international and resourcelimited environments Ephraim Tsalik , Professor, Duke University School of Medicine	Real world registry evidence in support of antimicrobial stewardship Jill Massey , Senior Vice President, Medical Affairs, Melinta Therapeutics	Current state by state regulations for hospital infection reporting, safety and infection control standards, and reality of nation-wide regulation for hospital infection reporting?	Synthesizing complex molecules for antibacterial products – manufacturing challenges and opportunities Jacques Dumas , Chief Scientific Officer, Tetraphase Pharmaceuticals	Developing phage drugs as first-line therapies Alexander Belcredi , Chief Executive Officer, PhagoMed Biopharma
						Biotech Pitches
						Epidermicin NI01, template for a new class of broad spectrum antimicrobials Mathew Upton , Founder and Chief Scientific Officer, Amprologix
						12:05



THURSDAY, NOVEMBER 7TH, 2019

ANTIBIOTIC R&D	DIAGNOSTICS	ANTIMICROBIAL STEWARDSHIP	INFECTION CONTROL	MANUFACTURING	PITCH&PARTNER₂₀₁₉
---------------------------	--------------------	----------------------------------	--------------------------	----------------------	---

Early Development	Development	Stewardship Partnerships	Guidelines and Regulation	Supply Chain	Biotech Pitches
--------------------------	--------------------	---------------------------------	----------------------------------	---------------------	------------------------

12:15	<p>How degrading residual antibiotics in the GI tract may prevent the emergence of anti-microbial resistance in the gut microbiome Sheila Connelly, Vice President of Research, Synthetic Biologics</p>	12:15
12:25	<p>GOLD SPONSOR SESSION If you are interested in sponsoring this session in the Diagnostics Track, contact André Singer now at +1 646 619 1797 or andre.singer@terrapinn.com</p>	12:25
12:35	<p>GOLD SPONSOR SESSION If you are interested in sponsoring this session in the Antimicrobial Stewardship Track, contact André Singer now at +1 646 619 1797 or andre.singer@terrapinn.com</p>	12:35
12:35	<p>GOLD SPONSOR SESSION If you are interested in sponsoring this session in the Infection Control Track, contact André Singer now at +1 646 619 1797 or andre.singer@terrapinn.com</p>	12:35
12:35	<p>GOLD SPONSOR SESSION If you are interested in sponsoring this session in the Manufacturing Track, contact André Singer now at +1 646 619 1797 or andre.singer@terrapinn.com</p>	12:35
12:35	<p>DNA Pol IIIC inhibitors for gram-positive infections, novel first in class antibiotic now in clinic Bob DeLuccia, Co-founder and Managing Partner, Acurx Pharmaceuticals</p>	12:35
12:35	<p>PhageBank - Advancing personalized phage therapy from niche to broad market scale Greg Merrill, Chief Executive Officer, Adaptive Phage Therapeutics</p>	12:35

12:35 NETWORKING LUNCH BREAK

1:05 **Keynote Address: What companies are doing to combat AMR and support appropriate use of anti-infective medicines**
 Moderator: **available for sponsorship**
Bruce Altevogt, Vice President and Head External Medical Engagement, Hospital Business Unit, **Pfizer Inc.**
Jayasree K. Iyer, Executive Director, **Access to Medicine Foundation**
Silas Holland, Director of Infectious Diseases Policy, **Merck**

1:35 NETWORKING LUNCH RESUMES

2:10 **ROUNDTABLES**

<p>Roundtable 1: Animal Health – examining stewardship progress in managing antibiotic use and potential AMR in Animal Health Moderator: Rick Sibbel, Former Executive Director, US Food Animal Business Unit, Merck Animal Health Brian Lubbers, Associate Professor, Kansas State University Paul Plummer, Executive Director, National Institute of Antimicrobial Resistance Research and Education (NIAMRRE)</p>	<p>Roundtable 2: Controlling c.diff – determining who to test how to prevent additional outbreaks in the hospital Kartik Cherabuddi, Director, Antimicrobial Stewardship Program and Hospital Epidemiologist, University of Florida</p>
<p>Roundtable 3: Innovation & stewardship – Advancing narrow spectrum, new mechanism antibiotics as precision agents to by-pass resistance and to support antibiotic stewardship. Developing the right antibiotic to treat the right patient and improve clinical outcomes. Dave Powell, Head of Research and SVP, Summit Therapeutics Richard Vickers, Chief Scientific Officer and SVP, Antimicrobials, Summit Therapeutics</p>	<p>Roundtable 4: Customizing Epic – use of Epic Stewardship Navigator to aid antimicrobial stewardship, pharmacist workflow, and prescribing habits in a tertiary cancer center Justine Ross, Infectious Diseases Pharmacist, Chair Antimicrobial Stewardship Program, Department of Pharmacy Services, City of Hope National Medical Center</p>
<p>Roundtable 5: Antimicrobial value assessment – a look into the role of HTA in the UK’s testing of novel assessment and delinked payment program Colm Leonard, Clinical Advisor, The National Institute for Health and Care Excellence (NICE)</p>	<p>Roundtable 6: Policy in Africa – advancing advocacy, political commitment, resistance data collection and Africa-wide stewardship guidelines for antimicrobial use in humans Jay Varma, Senior Advisor, Africa Centres for Disease Control and Prevention</p>
<p>Roundtable 7: Non-traditional antibacterials – advancing non-traditional product types from discovery phase to clinical development Brian Tse, Health Scientist, BARDA</p>	<p>Roundtable 8: Advancing preclinical – working with regulators through pre-clinical to advance distinct classes of small molecule drugs Ryan Devies, Chief Executive Officer, Curza</p>
<p>Roundtable 9: Supporting development – NIH programs filling the gaps in traditional and non-traditional therapeutic discovery & development with grants, contracts, in-vitro and in vivo screening and manufacturing capabilities and more Jane Knisely, Program Officer, NIH-NIAID</p>	<p>Roundtable 10: Market access – overcoming access barriers for smaller markets and considerations for countries and developers Christine Árdal, Senior Advisor, EU-JAMRAI, Norwegian Institute of Public Health</p>
<p>Roundtable 11: Patient advocacy – what can the growing antibiotic patient advocacy community do to generate public awareness and support for AMR initiatives Christian Lillis, Executive Director, Peggy Lillis Foundation</p>	<p>Roundtable 12: Candida auris – a ticking time bomb: responding to an urgent global public health threat Marco Taglietti, President and Chief Executive Officer, SCYNEXIS</p>

2:10

ROUNDTABLES

2:10

Roundtable 13: Phage development – Opportunities in development of novel phage therapies
Dave Ousterout, Chief Scientific Officer & Co-Founder, **Locus Biosciences**

 ANTIBIOTIC R&D	 DIAGNOSTICS	 ANTIMICROBIAL STEWARDSHIP	 INFECTION CONTROL	 MANUFACTURING	PITCH&PARTNER₂₀₁₉
---	--	--	--	--	---

Trial Design	Diagnostics in the Hospital	In-patient	Resistant Pathogen Protocol & Practices	Waste Management	Funding & Partnerships
---------------------	------------------------------------	-------------------	--	-------------------------	-----------------------------------

3:15

Novel trial designs for non-traditional anti-infectives – lessons learned from the Exebacase superiority design trial
Cara Cassino, Chief Medical Officer and Executive Vice President of Research and Development, **ContraFect**

A-Z of hospital and pharmacy use of new and existing rapid diagnostics –diagnosing multi drug resistant organisms
Eric Wenzler, Assistant Professor, Department of Pharmacy Practice, **University of Illinois at Chicago College of Pharmacy**

A coordinated approach to state-wide stewardship goals
Erica Washington, Healthcare-associated Infections and Antibiotic Resistance Program Coordinator, **Louisiana Department of Health**

Screening for gram negative bacteria – when to screen, who to screen, how to screen?
Michelle A. Barron, Medical Director, UCH Infection Prevention and Control, Professor of Medicine, **University of Colorado Denver**

Update on AMR and environmental manufacturing
Steve Brooks, Advisor, **AMR Industry Alliance**

Leveraging sources of public funding to meet gaps in S&M antibiotic financing - how can we avoid the catastrophic disappearance of S&M companies and their unique competencies in antibiotic discovery and development
Jean-Pierre Paccaud, Director, Business Development and Corporate Strategy, **Global Antibiotic R&D Partnership (GARDP)**

3:15

3:35

Working with regulators to advance non-traditional therapies to prevent and treat life-threatening infections in surgery and trauma
Michael P. Bevilacqua, Chief Executive Officer, **Amicrobe**

A major biofilm issue: early detection of Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis
Laia Fernandez, Research Laboratory Coordinator, Ciberes-IDIBAPS, Associate Professor, **University of Barcelona**

Implementation of an antimicrobial stewardship program across a multi-site health system - A Canadian Perspective
Kim Abbass, Antimicrobial Stewardship, Eastern Zone, **Nova Scotia Health Authority**

C. diff and C-suite headaches- reimbursement, outbreaks, and recurrence
Kerry LaPlante, President, **Society of Infectious Diseases Pharmacists (SIDP)**, Professor of Pharmacy, **University of Rhode Island**, Adjunct Professor of Medicine, **Brown University**

Future outlook & best practices for manufacturing to reduce AMR: sustainable frameworks and emerging technologies
Dale L. Stemple, Head Global EHS - North America and EMEA, Global Environmental, Health and Safety **Mylan**

UK Centre of Excellence - a global resource for pre-clinical and clinical development, and mobilizing public, private and philanthropic investment
Peter Jackson, Director, **AMR Centre**

3:35

Biotech Pitches

3:55

Panel: efforts to tackle the toughest clinical trials for antibiotic development - HABP/VABP & blood stream infections and more
Moderator: **Marina Kozak**, Biologist, Division of CBRN Countermeasures, **HHS/BARDA**
Pamela Tenaerts, Executive Director, **Clinical Trials**
Dennis Michael Dixon, Chief Bacteriology and Mycology Branch, **NIAID-NIH**
Sue Cammarata, Chief Medical Officer, **Melinta Therapeutics**

Panel: Evaluating novel diagnostics for hospital use and uptake in the clinic- considerations for cost, personnel training, and microbiologist
Moderator: **Sandy Estrada**, Vice President, Medical Affairs, **T2 Biosystems** and President, **Florida Society of Health System Pharmacists**
Cecile Balding, Microbiology Supervisor, **AdventHealth Daytona Beach**
Christopher Doern, Director of Clinical Microbiology, **Virginia Commonwealth University Health System**
Baoming Liu, Clinical Laboratory Specialist, **The Johns Hopkins Hospital**

When and how to prescribe new agents - best practices for understanding resistance and effectiveness of new antibiotics
Liza Vaezi, Co-Director Antimicrobial Stewardship Program/ Coordinator Pharmacy and Therapeutics, Virginia Mason Medical Center, Clinical Associate Professor, **University of Washington**

Isolation - when to isolate, who to isolate - Is healthcare moving away from isolation?
Daniel Morgan, Associate Professor, Epidemiology & Public Health, **University of Maryland School of Medicine**

Challenges with assessing and managing the environmental risks of antibiotics and AMR
Jason Snape, Senior Principal Environmental Scientist and SHE Foresight and Research Director, **AstraZeneca**

XF-73 for the prevention of post-surgical staphylococcal infections
Neil Clark, Chief Executive Officer, **Destiny Pharma**

3:55

A novel immunotherapy to fight infection and inflammation
Rusty Bromley, Chief Operating Officer, **AyuVis Research**

4:05

4:15

Required for chronic infections, antibiofilm drugs are coming
Thierry Bernardi, Chief Executive Officer, **BioFilm Pharma**

GOLD SPONSOR SESSION
If you are interested in sponsoring this session in the Infection Control Track, contact André Singer now at +1 646 619 1797 or andre.singer@terrapinn.com

GOLD SPONSOR SESSION
If you are interested in sponsoring this session in the Manufacturing Track, contact André Singer now at +1 646 619 1797 or andre.singer@terrapinn.com

Antabio SAS: novel antibacterials targeting critical priority MDR gram-negative pathogens
Marc Lemonnier, Chief Executive Officer, **Antabio**

4:15

BV100 to treat serious bacterial infections by A.baumannii
Marc Gitzinger, Chief Executive Officer & Co-Founder, **BioVersys AG**

4:25

4:35

4:35

PLENARY KEYNOTES

SUPPORTED BY BD

5:15	<p>CDC Keynote Address: A Look Forward and Back in Combatting AR Michael Craig, Senior Advisor for Antibiotic Resistance, Antibiotic Resistance Coordination and Strategy Unit, Centers for Disease Control</p>	5:15
5:25	<p>Keynote Panel: Benchmarking and risk-adjusting antimicrobial use: success, barriers, and future Moderator: Kalvin Yu, Medical Director, BD Digital Health MedMined Adam Zerda, Director, AMR Strategy and Development, BD Cliff MacDonald, Associate Director for Science, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Disease, Centers for Disease Control Eddie Stenehjem, Medical Director, Antibiotic Stewardship, Intermountain Healthcare Matthew Goetz, Chief, Infectious Diseases, VA Greater Los Angeles Healthcare System</p>	5:25
6:15	<p>Welcoming remarks by AMR Industry Alliance Thomas Cueni, Director-General, IFPMA, Chairman, AMR Industry Alliance</p>	6:15
<p>Cocktail reception hosted by AMR Industry Alliance</p>		









PLENARY KEYNOTES

SHIFTING PARADIGMS

9:00	<p>Keynote address: Patient and public outcry – examining the human impact of AMR and how we can make it a mainstream issue Mary Millard, Patient Advocate, Sepsis Survivor Christian Lillis, Executive Director, Peggy Lillis Foundation</p>	9:00
9:25	<p>Keynote Address: The impact of rapid, direct-from-blood diagnostics in enabling changes in clinical decisions and improving outcomes Tom Lowery, Chief Scientific Officer, T2 Biosystems</p>	9:25
9:50	<p>Keynote address: 360 of hospital purchasing and antibiotic use – understanding price-based vs stewardship-based purchasing decisions for new antibiotics & diagnostics Moderator: Debbie Goff, Infectious Diseases Specialist, The Ohio State University Wexner Medical Center, Clinical Associate Professor, The Ohio State University College of Pharmacy Jason Pogue, President-Elect, Society of Infectious Disease Pharmacists (SIDP) Thomas File, Antimicrobial Stewardship Program at Summa Health, Akron, President-Elect, Infectious Disease Society of America (IDSA)</p>	9:50

10:30 NETWORKING COFFEE BREAK 10:30

	 ANTIBIOTIC R&D	 DIAGNOSTICS	 ANTIMICROBIAL STEWARDSHIP	 INFECTION CONTROL	 VACCINES	
	Commercial & Partnerships	Industry Collaboration	Out-patient	Environment & Cleaning	Uptake and prevention	Investment
11:15	<p>Pilot reimbursement models to ensure access of new antibiotics in Sweden - Collaboration between industry and government agencies to ensure a model that works for all stakeholders Jenny Hellman, Analyst, Public Health Agency of Sweden</p>	<p>Reversing the “pitch” between diagnostics providers and industry - benefits and feasibility of pharma communicating their needs diagnostic developers first to accelerate development of badly needed tests Mary Motyl, Director of Clinical Microbiology, Merck and Co</p>	<p>Pharmacists on the front lines of outpatient care- Examining the critical role pharmacists & point of care diagnostics play in appropriate outpatient antibiotic use Charley John, Director, US Public Policy, Walgreen Co.</p>	<p>Making sense of all the infection control guidelines for surfaces and environments in hospitals Linda Lybert, Founder and Executive Director, Healthcare Surfaces Institute</p>	<p>Linking vaccine use to AMR reduction – Do we have enough evidence to convince policy makers to incorporate vaccines into broader AMR strategies Jim Wassil, Business Unit Lead, Vaccines, Patient & Health Impact, Pfizer</p>	<p>Investors Panel: Promising science in the field of antibiotic diagnostics and how developers can best approach investors Moderator: available for sponsorship Walter Stockinger, Managing Partner, Hadean Ventures Mary Schaheen, President and Director, Prevail Partners Cristina Montero, Associate Director, TechAtlas RA Capital Management</p>
11:35	<p>Short and long-term payment strategies for a sustainable market – impact of NTAP modifications, DRG carve-out, and potential subscription models Monika Schneider, Research Associate, Duke Margolis Center for Health Policy</p>	<p>Diagnostic engagement through antibiotic clinical development & commercialization – can further collaboration be attached to collectively tackle AMR? Ian Critchley, Vice President, Microbiology, Spero Therapeutics</p>	<p>Urgent care – antibiotic stewardship’s new frontier? Eddie Stenebjem, Medical Director, Antibiotic Stewardship, Intermountain Healthcare</p>	<p>GOLD SPONSOR SESSION If you are interested in sponsoring this session in the Infection Control Track, contact André Singer now at +1 646 619 1797 or andre.singer@terrapinn.com</p>	<p>The role of vaccination in Antimicrobial Stewardship (AMS) and Merck’s One Health approach to tackling the challenge of AMR Allison Flinn, Associate Director, Public Policy and Government Relations, Merck Animal Health</p>	<p>Diagnostics Pitches</p>
11:55	<p>Panel: How to foster private investment in antibiotic development? Exploring an impact investment fund Peter Beyer, Senior Advisor, World Health Organization Marc Gitzinger, Chief Executive Officer and Co-Founder, BioVersys AG Anand Anandkumar, Chief Executive Officer, Bugworks Research India</p>	<p>GOLD SPONSOR SESSION If you are interested in sponsoring this session in the Diagnostics Track, contact André Singer now at +1 646 619 1797 or andre.singer@terrapinn.com</p>	<p>Transition of care in antimicrobial stewardship from in-patient to out-patient- exploring barriers and solutions to optimize antibiotic use Susan Davis, Clinical Professor, Pharmacy Practice, Wayne State University, Infectious Diseases Pharmacist, Henry Ford Health System</p>	<p>Panel: Getting C-suite buy-in for new hospital infection control products and technologies - weighing risks and liabilities of taking on new infection control technologies Moderator: available for sponsorship Jeffrey Silvers, Medical Director of Pharmacy and Infection Control Sutter Health Marisa Glucoft, Director, Infection Prevention Control, Children’s Hospital Los Angeles Dorine Berriel-Cass, Director, Infection Prevention and Control, Spectrum Health</p>	<p>A novel toxoid vaccine targeting Staphylococcus aureus virulence Javad Aman, President and Chief Scientific Officer, Integrate BioTherapeutics</p>	<p>Quorum X Diagnostics: A new way of identifying bacteria, without the need for culture or DNA amplification Maria Nagy, Chief Executive Officer, Quorum X Diagnostics</p>
						<p>Aperture Bio empiriSTAT UTI: A rapid, direct-out-of-urine method for addressing the rise in antibiotic resistance in urinary tract infections Matthew Gombrich, Chief Medical Officer, Aperture Bio</p>

 ANTIBIOTIC R&D	 DIAGNOSTICS	 ANTIMICROBIAL STEWARDSHIP	 INFECTION CONTROL	 MANUFACTURING	PITCH&PARTNER₂₀₁₉
---	--	--	--	--	---

Commercial & Partnerships	Industry Collaboration	Out-patient	Environment & Cleaning	Uptake and prevention	Diagnostics Pitches
--------------------------------------	-------------------------------	--------------------	-----------------------------------	------------------------------	----------------------------

12:15	Panel discussion continued	Session continued	GOLD SPONSOR SESSION If you are interested in sponsoring this session in the Antimicrobial Stewardship Track, contact André Singer now at +1 646 619 1797 or andre.singer@terrapinn.com	Panel discussion continued	An Established Tool to Address New Challenges in Anti-Microbial Resistance Jacqueline Miller , Vice President and Head, Clinical R&D, US Vaccine Research and Development Center, GSK Vaccines	12:15 Bacteromic: Intelligence for precision therapies against antimicrobial resistance Piotr Garstecki , Chief Executive Officer, Bacteromic
						12:25 Academia Pitches Discovery of antimicrobial peptides from alligator and komodo dragons against multi-drug resistant bacteria Monique van Hoek , Professor School of Systems Biology, George Mason University

12:35 NETWORKING LUNCH BREAK

1:00	C-Suite Keynote Panel: Balancing continued innovation in R&D while navigating funding, stewardship and the overall commercial landscape Moderator: available for sponsorship Manos Perros , Chief Executive Officer, Entasis Therapeutics Mike Dudley , President & Chief Executive Officer, Qpex Biopharma David Roblin , Chief Operating Officer, Chief Medical Officer, President of R&D, Summit Therapeutics Guy Macdonald , President and Chief Executive Officer, Tetraphase John Johnson , Chief Executive Officer and Director, Melinta Therapeutics	1:00
------	--	------

1:40 NETWORKING LUNCH BREAK RESUMES

2:10 **ROUNDTABLES**

Roundtable 1: Moving policy forward – payment reform, public perception and continued efforts in 2020 Moderator: Jeremy Knox , Senior Investment Director, Wellcome Trust Monika Schneider , Research Associate, Duke Margolis Center for Health Policy	Roundtable 2: The fecal microbiome – new approaches to the treatment of C. difficile infection Nick VanHise , Infectious Disease Clinical Pharmacy Specialist, Research Coordinator, Metro Infectious Disease Consultants & Cdif Foundation
Roundtable 3: Evaluating Diagnostics – Criteria for potential coverage and related decisions - paths for generating, formalizing, & analysing evidence to build & reach consensus Eugean Jiwamall , Senior Research Analyst, Technology Evaluation & Medical Policy, Independence Blue Cross	Roundtable 4: AMR and Sepsis – we are all in this together Thomas Heymann , President & Executive Director, Sepsis Alliance
Roundtable 5: Surveillance – examining novel metrics for measurement, societal and socioeconomic factors effecting resistance, and how resistance surveillance tools can help educate policymakers on AMR Eili Klein , Fellow, Center for Disease Dynamics, Economics & Policy	Roundtable 6: Stewardship best practices – highlights of specific hospital protocols and team collaborations Gul Madison , Head of Infectious Disease, Mercy Philadelphia Hospital Tom Turco , Clinical Pharmacist, Mercy Philadelphia Hospital
Roundtable 7: Infection prevention – next wave of infection prevention of multidrug resistant infections through screening, protocol and more Angella Browne , Infection Control Officer, Howard University Hospital	Roundtable 8: CARB-X accelerator – company perspective on CARB-X Accelerator - What worked and what can be improved? Jeanette Mucha , CEO, Chief Science Officer and Co-Founder, Scibac
Roundtable 9: Health Technology Assessment – when it comes to AMR, will HTA be part of the solution or part of the problem? Abigail Colson , Lecturer, Department of Management Science, University of Strathclyde Glasgow	Roundtable 10: Microbiome & CDC – Discussing a vision for precision public health and novel approaches to infection prevention through the microbiome Clifford McDonald , Associate Director for Science, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Disease, Centers for Disease Control

2:10

ROUNDTABLES

2:10

Roundtable 11: The role of vaccines in controlling AMR

Marc Lipsitch, Professor of Epidemiology, Department of Epidemiology, Department of Immunology and Infectious Diseases, Center for Communicable Disease Dynamics, **Harvard T.H. Chan School of Public Health**

Roundtable 12: Infection intervention – using the microbiome to make antibiotics effective again

Lee Jones, President and Chief Executive Officer, **Rebiotix**

Roundtable 13: Patient practitioner education – how hospitals can and should educate patients on infection risks and easy to implement prevention practices

Mary Millard, Patient advocate, **Sepsis Survivor**

Roundtable 14: Candida auris – a ticking time bomb: responding to an urgent global public health threat

Marco Taglietti, President, Chief Executive Officer, **SCYNEXIS**



ANTIBIOTIC R&D



DIAGNOSTICS

Early Development

Development

3:15

Innovative business partnerships to build a portfolio of novel antibiotics

Zak Zimmerman, Chief Executive Officer, **Forge Therapeutics**

3:15

FebriDx: A POC test that simultaneously detects MxA and CRP during presumed acute respiratory infection to improve clinical workflow, reduce unnecessary antibiotics, and save costs

Robert Sambursky, President and Chief Executive Officer, **RPS Diagnostics**

3:35

Rationale for in-licensing early stage antibacterial assets

Terry Roemer, President and Chief Scientific Officer, **Prokaryotics**

3:35

VALUE-DX: generating evidence on the medical, economic, and public health value of diagnostics in tackling AMR

Herman Goossens, Project Leader, Value-DX, Director of Research, Laboratory of Medical Microbiology, **University of Antwerp**

3:55

END OF CONFERENCE

3:55



ROUNDTABLES

1. Candida auris – a ticking time bomb: responding to an urgent global public health threat

Marco Taglietti, President & Chief Executive Officer, **SCYNEXIS**

4. Water quality – understanding transmission of waterborne pathogens and how the international community can combat the spread of resistance through integrating advanced lab techniques and treatment

Amy Kirby, Senior Service Fellow, **CDC**

7. Infection intervention – using the microbiome to make antibiotics effective again

Courtney Jones, Senior Project Manager, Upstream Marketing Manager, **Rebiotix**

10. Moving policy forward – payment reform, public perception and continued efforts in 2020

Moderator: **Jeremy Knox**, Senior Investment Director, **Wellcome Trust**

Monika Schneider, Research Associate, **Duke Margolis Center for Health Policy**

13. CARB-X accelerator – company perspective on CARB-X Accelerator - What worked and what can be improved?

Jeanette Mucha, CEO, Chief Science Officer and Co-Founder, **Scibac**

16. Microbiome & CDC – Discussing a vision for precision public health and novel approaches to infection prevention through the microbiome

Clifford McDonald, Associate Director for Science, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Disease, **Centers for Disease Control**

19. Controlling c.diff – determining who to test, how to prevent additional outbreaks in the hospital

Kartik Cherabuddi, Director, Antimicrobial Stewardship Program and Hospital Epidemiologist, **University of Florida**

2. Phage development – opportunities in development of novel phage therapies

Dave Ousterout, Chief Scientific Officer & Co-Founder, **Locus Biosciences**

5. Drug dosing – anti-infective underdosing and opportunities for customized drug dosing

Jeffrey Cies, Pharmacy Clinical Coordinator, **St. Christopher's Hospital for Children in Philadelphia**

8. Patient practitioner education – how hospitals can and should educate patients on infection risks and easy to implement prevention practices

Mary Millard, Patient Advocate, **Sepsis Survivor**

11. The fecal microbiome – new approaches to the treatment of C. difficile infection

Nick VanHise, Infectious Disease Clinical Pharmacy Specialist, Research Coordinator, **Metro Infectious Disease Consultants & Cdif Foundation**

14. SPARK Platform – Pew Charitable Trusts' collaborative discovery tool for gram-negative antibiotics

Wes Kim, Antibiotic Resistance Project, **The Pew Charitable Trust**

17. Non-traditional antibacterials – advancing non-traditional product types from discovery phase to clinical development

Brian Tse, Health Scientist, **BARDA**

20. Innovation & stewardship – advancing narrow spectrum, new mechanism antibiotics as precision agents to by-pass resistance and to support antibiotic stewardship. Developing the right antibiotic to treat the right patient and improve clinical outcomes

Dave Powell, Head of Research and SVP, **Summit Therapeutics**
Richard Vickers, Chief Scientific Officer and SVP, Antimicrobials, **Summit Therapeutics**

3. Global collaboration – global stakeholder collaboration between clinicians, policy makers, pharmaceutical/diagnostic companies is needed to succeed at ASP

Debbie Goff, Infectious Diseases Specialist, **Ohio State University, College of Pharmacy**

6. Developing diagnostics – novel approaches to development

Minh-Hong Nguyen, Director, Transplant Infectious Diseases, Director, Antimicrobial Management Program, Infectious Diseases, Dept of Medicine, **University of Pittsburgh**

9. Supporting development – NIH programs filling the gaps in traditional and non-traditional therapeutic discovery & development with grants, contracts, in-vitro and in vivo screening and manufacturing capabilities and more

Jane Knisely, Program Officer, **NIH-NIAID**

12. Infection prevention – next wave of infection prevention of multidrug resistant infections through screening, protocol and more

Angella Browne, Infection Control Officer, **Howard University Hospital**

15. Health Technology Assessment – when it comes to AMR, will HTA be part of the solution or part of the problem?

Abigail Colson, Lecturer, Department of Management Science, **University of Strathclyde Glasgow**

18. Patient practitioner education – how hospitals can and should educate patients on infection risks and easy to implement prevention practices

Mary Millard, Patient advocate, **Sepsis Survivor**

21. Customizing Epic – use of Epic Stewardship Navigator to aid antimicrobial stewardship, pharmacist workflow, and prescribing habits in a tertiary cancer center
Justine Ross, Infectious Diseases Pharmacist, Chair Antimicrobial Stewardship Program, Department of Pharmacy Services, **City of Hope National Medical Center**



Good opportunities for pipeline information, networking, and potentially presenting your own companies' data

Clinical Solutions Executive, **Cepheid**

Quite interactive, very good opportunity to learn about future trends

Head of Marketing & Scientific Affairs, **Curetis GmbH**



Great opportunity to network, and hear the perspectives of CEOs, FDA and other key health leaders on issues related to antimicrobial resistance

Infectious Diseases Specialist, **Ohio State University, College of Pharmacy**



Attendance by key global players ... Absolutely a case of "Be there or be square!"

Executive Vice President, **Recce Pharmaceuticals**

NETWORKING APP

Our full service app allows you to manage your time efficiently and effectively at the event, while ensuring you meet all the right people.

The app will go live 6 weeks before the event. At that time, you will receive an email with your personalised login.

The app is available on desktop as well as the app store.



DIRECT MESSAGING / 1-2-1 MEETINGS

You can view and message speakers, sponsors and attendees to set up on site meetings & share content leading up to & at the event. Scheduled meetings will take place in the networking zone at a reserved table.



AGENDA

Use the app to view the most up to date agenda & highlight the sessions you want to attend. You can create your own personal schedule!



FLOORPLAN

Be sure to check out the floorplan to ensure you aren't missing out on meeting with exhibitors and activities happening on the exhibition floor.



SOCIAL MEDIA

Be sure to check out the floorplan to ensure you aren't missing out on meeting with exhibitors and activities happening on the exhibition floor.



LIVE EVENT NOTIFICATIONS

Be sure to check out the floorplan to ensure you aren't missing out on meeting with exhibitors and activities happening on the exhibition floor.

Note: Jujama respects your privacy and assures you that all of your personal contact information will be kept confidential. Rest assured that no contact information will be shared via our platform.

REGISTER NOW

2 DAY PASS

\$2,000

BOOK YOUR PASS BY SEPTEMBER 13 TO SAVE 30%

Bringing the price to

\$1,600

BOOK A GROUP OF 3 OR MORE AND SAVE AN ADDITIONAL 30%

Bringing the price to

\$1,120

Register now at www.terrapinn.com/antimicrobial

2019 SPONSORS

PLATINUM SPONSOR




GOLD SPONSORS



SILVER SPONSOR



BRONZE SPONSORS



EXHIBITORS

